C.J.A. Punt

7.5k total citations
22 papers, 404 citations indexed

About

C.J.A. Punt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, C.J.A. Punt has authored 22 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in C.J.A. Punt's work include Colorectal Cancer Treatments and Studies (6 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). C.J.A. Punt is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). C.J.A. Punt collaborates with scholars based in Netherlands, Germany and Belgium. C.J.A. Punt's co-authors include Jesús Gómez-Navarro, Martijn G.H. van Oijen, Axel Hauschild, J.B.A.G. Haanen, Richard Kefford, Dmitri Pavlov, Claus Garbe, A. Ribas, V.E.P.P. Lemmens and G.J. Creemers and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

C.J.A. Punt

22 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C.J.A. Punt Netherlands	8	356	120	105	72	72	22	404
Andy Blake-Haskins United States	8	379 1.1×	201 1.7×	126 1.2×	63 0.9×	30 0.4×	13	419
Eduardo Huertas Argentina	9	208 0.6×	159 1.3×	57 0.5×	95 1.3×	50 0.7×	19	390
Quanren Wang China	11	314 0.9×	76 0.6×	169 1.6×	103 1.4×	77 1.1×	25	440
Pranshu Bansal United States	11	289 0.8×	67 0.6×	218 2.1×	50 0.7×	121 1.7×	21	510
М. В. Копп Russia	11	188 0.5×	52 0.4×	98 0.9×	56 0.8×	102 1.4×	16	359
H. Rückle-Lanz Germany	5	254 0.7×	36 0.3×	81 0.8×	67 0.9×	55 0.8×	6	347
R Canaletti Italy	6	171 0.5×	51 0.4×	63 0.6×	51 0.7×	106 1.5×	7	309
S. Nagel Germany	10	239 0.7×	68 0.6×	207 2.0×	46 0.6×	76 1.1×	29	421
J. Schüller Austria	11	251 0.7×	22 0.2×	69 0.7×	61 0.8×	58 0.8×	30	351
Eduardo Yáñez Chile	10	247 0.7×	40 0.3×	106 1.0×	134 1.9×	28 0.4×	26	314

Countries citing papers authored by C.J.A. Punt

Since Specialization

Citations

This map shows the geographic impact of C.J.A. Punt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.J.A. Punt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.J.A. Punt more than expected).

Fields of papers citing papers by C.J.A. Punt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.J.A. Punt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.J.A. Punt. The network helps show where C.J.A. Punt may publish in the future.

Co-authorship network of co-authors of C.J.A. Punt

This figure shows the co-authorship network connecting the top 25 collaborators of C.J.A. Punt. A scholar is included among the top collaborators of C.J.A. Punt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.J.A. Punt. C.J.A. Punt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Versteijne, Eva, Jacob L. van Dam, Mustafa Suker, et al.. (2021). Improved Overall Survival in Pancreatic Cancer with Preoperative Chemoradiotherapy: Long-term Results of the PREOPANC Trial. HPB. 23. S672–S673. 3 indexed citations

Wilmink, Johanna W., Nadia Haj Mohammad, Jeroen Hagendoorn, et al.. (2020). Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. Critical Reviews in Oncology/Hematology. 151. 102975–102975. 13 indexed citations

Kwakman, R., Arnold Baars, Henk Boot, et al.. (2017). Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in Western cancer patients. European Journal of Cancer. 72. S69–S69. 1 indexed citations

Vink, Geraldine R., et al.. (2017). The Prospective Dutch ColoRectal Cancer cohort (PLCRC) − a prospective nationwide observational cohort study. European Journal of Cancer. 72. S55–S55. 1 indexed citations

Bos, Amanda C. R. K., Felice N. van Erning, Yvette R.B.M. van Gestel, et al.. (2015). Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. European Journal of Cancer. 51(17). 2553–2561. 81 indexed citations

Lesterhuis, W. Joost, et al.. (2010). Skin-derived tumor specific T cells predict clinical outcome in dendritic cell vaccination studies in both stage III and IV melanoma patients. Journal of Translational Medicine. 8(S1). 1 indexed citations

Koopman, Miriam, Sabine Venderbosch, Ninja Antonini, J. Han van Krieken, & C.J.A. Punt. (2008). The correlation between ERCC1 expression and outcome of chemotherapy in patients with advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group study (DCCG). Journal of Clinical Oncology. 26(15_suppl). 11042–11042. 1 indexed citations

Ribas, A., Axel Hauschild, Richard Kefford, et al.. (2008). Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. Journal of Clinical Oncology. 26(15_suppl). LBA9011–LBA9011. 127 indexed citations

Marijnen, Corrie A.M., Hans De Wilt, Margot Tesselaar, et al.. (2008). Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: A feasibility study of the Dutch Colorectal Cancer Group (DCCG). Journal of Clinical Oncology. 26(15_suppl). 15040–15040. 11 indexed citations

10.

Timmer-Bonte, Johanna N.H., C.J.A. Punt, Johan Bussink, et al.. (2007). Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung Cancer. 60(2). 222–230. 8 indexed citations

11.

Bouwhuis, Marna G., Stefan Suciu, François Salès, et al.. (2007). Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) compared to observation (obs). Journal of Clinical Oncology. 25(18_suppl). 8507–8507. 8 indexed citations

12.

Keilholz, Ulrich, Stefan Suciu, A. Y. Bedikian, et al.. (2007). LDH is a prognostic factor in stage IV melanoma patients (pts) but is a predictive factor only for bcl2 antisense treatment efficacy: Re-analysis of GM301 and EORTC18951 randomized trials. Journal of Clinical Oncology. 25(18_suppl). 8552–8552. 7 indexed citations

13.

Bouwhuis, Marna G., Stefan Suciu, Alessandro Testori, et al.. (2007). 5LB Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation. European Journal of Cancer Supplements. 5(6). 5–6. 7 indexed citations

14.

Berkmortel, Franchette W.P.J. van den, et al.. (2006). Severe encephalopathy after high-dose chemotherapy with autologous stem cell support for brain tumours.. Data Archiving and Networked Services (DANS). 26(1B). 729–33. 2 indexed citations

15.

Groenewegen, Gerard, S. Osanto, Hwanseok Rhee, & C.J.A. Punt. (2000). [Interferon for adjuvant therapy in melanoma; although approved, not indicated].. PubMed. 144(45). 2160–2. 3 indexed citations

16.

Fumoleau, P., Hoffmann-La Roche, Christian Dittrich, et al.. (2000). Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. UCL Discovery (University College London). 7 indexed citations

17.

Keilholz, Ulrich, C.J.A. Punt, M. Gore, et al.. (2000). Dacarbazine, cisplatin and IFN-alpha with or without IL-2 in advanced melanoma (EORTC trial 18951). Annals of Oncology. 11. 4. 15 indexed citations

18.

Keilholz, Ulrich, S.H. Goey, C.J.A. Punt, et al.. (1997). A randomized trial of IFN??/IL-2 with or without CDDP in advanced melanoma. Melanoma Research. 7(Supplement 1). S8–S8. 1 indexed citations

19.

Keilholz, Ulrich, S.H. Goey, C.J.A. Punt, et al.. (1997). A randomized trial of IFNα/IL-2 with or without CDDP in advanced melanoma: An EORTC melanoma cooperative group trial. European Journal of Cancer. 33. S256–S256. 1 indexed citations

20.

Keilholz, Ulrich, C.J.A. Punt, Carmen Scheibenbogen, et al.. (1996). A RANDOMIZED TRIAL OF IFN??/IL-2 WITH OR WITHOUT CDDP IN ADVANCED MELANOMA: AN EORTC MELANOMA COOPERATIVE GROUP TRIAL. Journal of Immunotherapy. 19(6). 458–458. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact